Caseware UK (AP4) 2025.0.111 2025.0.111 2026-03-312026-03-31falseThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.9falsetrueNo description of principal activity2025-04-018false 01524904 2025-04-01 2026-03-31 01524904 2024-04-01 2025-03-31 01524904 2026-03-31 01524904 2025-03-31 01524904 c:CompanySecretary1 2025-04-01 2026-03-31 01524904 c:Director1 2025-04-01 2026-03-31 01524904 c:RegisteredOffice 2025-04-01 2026-03-31 01524904 d:Buildings 2025-04-01 2026-03-31 01524904 d:Buildings 2026-03-31 01524904 d:Buildings 2025-03-31 01524904 d:Buildings d:OwnedOrFreeholdAssets 2025-04-01 2026-03-31 01524904 d:MotorVehicles 2025-04-01 2026-03-31 01524904 d:FurnitureFittings 2025-04-01 2026-03-31 01524904 d:OtherPropertyPlantEquipment 2025-04-01 2026-03-31 01524904 d:OtherPropertyPlantEquipment 2026-03-31 01524904 d:OtherPropertyPlantEquipment 2025-03-31 01524904 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2025-04-01 2026-03-31 01524904 d:OwnedOrFreeholdAssets 2025-04-01 2026-03-31 01524904 d:CurrentFinancialInstruments 2026-03-31 01524904 d:CurrentFinancialInstruments 2025-03-31 01524904 d:Non-currentFinancialInstruments 2026-03-31 01524904 d:Non-currentFinancialInstruments 2025-03-31 01524904 d:CurrentFinancialInstruments d:WithinOneYear 2026-03-31 01524904 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 01524904 d:Non-currentFinancialInstruments d:AfterOneYear 2026-03-31 01524904 d:Non-currentFinancialInstruments d:AfterOneYear 2025-03-31 01524904 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2026-03-31 01524904 d:Non-currentFinancialInstruments d:BetweenOneTwoYears 2025-03-31 01524904 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2026-03-31 01524904 d:Non-currentFinancialInstruments d:BetweenTwoFiveYears 2025-03-31 01524904 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2026-03-31 01524904 d:Non-currentFinancialInstruments d:MoreThanFiveYears 2025-03-31 01524904 d:ShareCapital 2026-03-31 01524904 d:ShareCapital 2025-03-31 01524904 d:RetainedEarningsAccumulatedLosses 2026-03-31 01524904 d:RetainedEarningsAccumulatedLosses 2025-03-31 01524904 c:FRS102 2025-04-01 2026-03-31 01524904 c:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 01524904 c:FullAccounts 2025-04-01 2026-03-31 01524904 c:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 01524904 d:HirePurchaseContracts d:WithinOneYear 2026-03-31 01524904 d:HirePurchaseContracts d:WithinOneYear 2025-03-31 01524904 d:HirePurchaseContracts d:BetweenOneFiveYears 2026-03-31 01524904 d:HirePurchaseContracts d:BetweenOneFiveYears 2025-03-31 01524904 6 2025-04-01 2026-03-31 01524904 d:AcceleratedTaxDepreciationDeferredTax 2026-03-31 01524904 d:AcceleratedTaxDepreciationDeferredTax 2025-03-31 01524904 d:MotorVehicles d:LeasedAssetsHeldAsLessee 2026-03-31 01524904 d:MotorVehicles d:LeasedAssetsHeldAsLessee 2025-03-31 01524904 d:LeasedAssetsHeldAsLessee 2026-03-31 01524904 d:LeasedAssetsHeldAsLessee 2025-03-31 01524904 e:PoundSterling 2025-04-01 2026-03-31 iso4217:GBP xbrli:pure
Registered number: 01524904







UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2026


CONSOLIDATED MEDICAL INDUSTRIES LIMITED







































 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
COMPANY INFORMATION


Director
Mr A Hodgson 




Company secretary
Mrs C Hodgson



Registered number
01524904



Registered office
CMI House
9 Millbanke Court

Millbank Way

Bracknell

Berkshire

RG12 1RP




Accountants
Menzies LLP
Chartered Accountants

Magna House

18-32 London Road

Staines-Upon-Thames

TW18 4BP





 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 



CONTENTS



Page
Statement of Financial Position
1 - 2
Notes to the Financial Statements
3 - 10


 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
REGISTERED NUMBER:01524904



STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2026

2026
2025
Note
£
£

Fixed assets
  

Tangible assets
 4 
696,837
138,537

  
696,837
138,537

Current assets
  

Stocks
  
146,844
196,042

Debtors: amounts falling due within one year
 6 
91,646
59,248

Bank and cash balances
  
59,756
128,337

  
298,246
383,627

Creditors: amounts falling due within one year
 7 
(284,943)
(167,049)

Net current assets
  
 
 
13,303
 
 
216,578

Total assets less current liabilities
  
710,140
355,115

Creditors: amounts falling due after more than one year
  
(363,460)
-

Provisions for liabilities
  

Deferred tax
 11 
(38,985)
(20,752)

  
 
 
(38,985)
 
 
(20,752)

Net assets
  
307,695
334,363


Capital and reserves
  

Called up share capital 
  
2,000
2,000

Profit and loss account
  
305,695
332,363

  
307,695
334,363


Page 1

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
REGISTERED NUMBER:01524904


    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2026

The director considers that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 


Mr A Hodgson
Director

Date: 7 August 2026

The notes on pages 3 to 10 form part of these financial statements.

Page 2

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

1.


General information

Consolidated Medical Industries Limited is a private company, limited by shares, incorporated in England and Wales. The address of the principal place of business and the registered office is given in the company information page within these financial statements.

The company's financial statements are presented in sterling which is the functional currency of the company and rounded to the nearest £.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Turnover is derived from the installation, repair, rental and sale of medical and pharmaceutical equipment and is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. 

 
2.3

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on both a reducing balance and straight-line basis.

Depreciation is provided on the following basis:

Land and buildings
-
2% straight-line
Motor vehicles
-
25% reducing balance
Fixtures and fittings
-
25% reducing balance
Other fixed assets
-
33% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 3

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)

 
2.4

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Statement of Income and Retained Earnings for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

 
2.5

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.6

Operating leases: the company as lessor

Rental income from operating leases is credited to profit or loss on a straight-line basis over the lease term.

Amounts paid and payable as an incentive to sign an operating lease are recognised as a reduction to income over the lease term on a straight-line basis, unless another systematic basis is representative of the time pattern over which the lessor's benefit from the leased asset is diminished.

 
2.7

Operating leases: the company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.8

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.

Page 4

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.Accounting policies (continued)

 
2.9

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.



3.


Employees

The average monthly number of employees, including directors, during the year was 9 (2025 - 8).

Page 5

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

4.


Tangible fixed assets


Land and buildings
Plant and machinery etc.
Total

£
£
£



Cost or valuation


At 1 April 2025
10,000
393,114
403,114


Additions
519,089
129,094
648,183


Disposals
-
(89,781)
(89,781)



At 31 March 2026

529,089
432,427
961,516



Depreciation


At 1 April 2025
10,000
254,577
264,577


Charge for the year on owned assets
10,382
71,630
82,012


Disposals
-
(81,910)
(81,910)



At 31 March 2026

20,382
244,297
264,679



Net book value



At 31 March 2026
508,707
188,130
696,837



At 31 March 2025
-
138,537
138,537

The net book value of assets held under finance leases or hire purchase contracts, included above, are as follows:


2026
2025
£
£



Motor vehicles
20,798
-

20,798
-

Page 6

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

5.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 April 2025
150,750



At 31 March 2026

150,750



Impairment


At 1 April 2025
150,750



At 31 March 2026

150,750



Net book value



At 31 March 2026
-



At 31 March 2025
-


6.


Debtors

2026
2025
£
£


Trade debtors
46,344
36,157

Other debtors
25,065
23,091

Prepayments and accrued income
20,237
-

91,646
59,248


Page 7

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

7.


Creditors: Amounts falling due within one year

2026
2025
£
£

Bank loans
17,445
-

Trade creditors
15,512
11,969

Corporation tax
-
21,462

Other taxation and social security
10,423
12,824

Obligations under finance lease and hire purchase contracts
4,178
-

Other creditors
228,085
110,996

Accruals and deferred income
9,300
9,798

284,943
167,049


The bank loan is secured on the company's freehold property by a fixed charge. Hire purchase contracts are secured against the assets to which they relate.


8.


Creditors: Amounts falling due after more than one year

2026
2025
£
£

Bank loans
345,114
-

Net obligations under finance leases and hire purchase contracts
18,346
-

363,460
-


The bank loan is secured on the company's freehold property by a fixed charge. Hire purchase contracts are secured against the assets to which they relate.

Page 8

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

9.


Loans


Analysis of the maturity of loans is given below:


2026
2025
£
£

Amounts falling due within one year

Bank loans
17,445
-


17,445
-

Amounts falling due 1-2 years

Bank loans
18,478
-


18,478
-

Amounts falling due 2-5 years

Bank loans
62,265
-


62,265
-

Amounts falling due after more than 5 years

Bank loans
264,371
-

264,371
-

362,559
-



10.


Hire purchase and finance leases


Minimum lease payments under hire purchase fall due as follows:

2026
2025
£
£


Within one year
4,178
-

Between 1-5 years
18,168
-

22,346
-

Page 9

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

11.


Deferred taxation




2026


£






At beginning of year
(20,752)


Charged to profit or loss
(18,233)



At end of year
(38,985)

The provision for deferred taxation is made up as follows:

2026
2025
£
£


Accelerated capital allowances
(38,985)
(20,752)

(38,985)
(20,752)


12.


Related party transactions

During the year, the following transactions between the director and company subsisted. This amount is considered to be interest free and repayable on demand.


2026
2025
£
£

Balance at beginning of year
18,091
(24,549)
Amounts advanced
750
62,640
Amounts repaid
(45,000)
(20,000)
(26,159)
18,091

 
Page 10